Donostiako Unibertsitate Ospitalea

Running trials

• Recruiting

  A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  2026-526654-14-01· Phase 3· Source

• Recruiting

  Heart Failure in Women: Epidemiological and Prognostic Insights

  NCT07847983· Source

• Not yet recruiting

  A phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation

  2026-525964-17-00· Phase 2· Source

• Recruiting

  BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer

  NCT07492641· Phase 3· Source

• Not yet recruiting

  A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

  NCT07578337· Phase 2· Source

• Recruiting

  Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

  NCT07478991· Phase 3· Source

• Recruiting

  A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis

  2025-525127-27-00· Phase 1/2· Source

• Recruiting

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· Phase 3· Source

• Not yet recruiting

  A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

  2024-516570-30-00· Phase 2· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Source

• Recruiting

  A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy

  2025-522979-29-00· Phase 3· Source

• Not yet recruiting

  Treatment for Ph-negative ALL for Adults up to 65 Years

  NCT07443592· Source

• Not yet recruiting

  SAVE trial

  2025-523709-13-00· Phase 3· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Source

• Recruiting

  Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

  NCT07217587· Phase 3· Source

• Recruiting

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· Phase 3· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Recruiting

  Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

  NCT07190690· Source

• Active, not recruiting

  Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

  NCT07287189· Phase 2· Source

• Not yet recruiting

  Study of the Influence of the Mediterranean Diet on the Quality of Life of Patients With Endometriosis.

  NCT07270393· Source

• Recruiting

  Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)

  NCT07414212· Phase 1/2· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  NCT07059845· Phase 2· Source

• Recruiting

  Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· Phase 3· Source

• Recruiting

  OMTX705-006 Phase 1b

  2025-521872-69-00· Phase 1· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Source

• Recruiting

  A study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain.

  2025-521152-34-00· Phase 2· Source

• Recruiting

  Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma

  2024-516233-12-00· Phase 1· Source

• Recruiting

  Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

  NCT07120503· Phase 2· Source

• Recruiting

  Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib and tislelizumab in patients with advanced/metastatic colorectal cancer

  2025-520743-33-00· Phase 1/2· Source

• Recruiting

  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  2023-510294-34-00· Phase 3· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

  NCT06821542· Phase 3· Source

• Recruiting

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· Phase 3· Source

• Recruiting

  A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  2023-507097-41-01· Phase 3· Source

• Recruiting

  Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  NCT06819007· Phase 3· Source

• Active, not recruiting

  Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD)

  2024-513384-15-00· Phase 2· Source

• Active, not recruiting

  A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT06686615· Source

• Active, not recruiting

  Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

  NCT06619236· Phase 3· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Source

• Active, not recruiting

  PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

  NCT06133517· Phase 2· Source

• Active, not recruiting

  Research study on the use of capivasertib together with fulvestrant in patients with advanced breast cancer who have relapsed/progressed to standard treatment reflecting actual clinical practice in Spain

  2024-513952-13-00· Phase 3· Source

• Not yet recruiting

  Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

  NCT06712030· Phase 3· Source

• Active, not recruiting

  Study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment in Patients with Advanced or Recurrent Endometrial Cancer in Spain.

  2024-514728-17-00· Phase 4· Source

• Recruiting

  Clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas

  2024-520318-23-00· Phase 1/2· Source

• Recruiting

  LATE-R trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

  2024-512835-53-00· Phase 2· Source

• Active, not recruiting

  A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy

  NCT04378647· Phase 2· Source

• Active, not recruiting

  Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

  NCT06602193· Phase 2· Source

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

  NCT06643481· Phase 2· Source

• Active, not recruiting

  LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

  NCT02205762· Phase 2/3· Source

Showing 50 of 112.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ovarian cancer6 recruiting
• Colorectal cancer4 recruiting
• Pancreatic cancer4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Heart failure3 recruiting
• Metastatic breast cancer3 recruiting
• Prostate cancer3 recruiting
• Acute myeloid leukaemia2 recruiting
• Amyloidosis2 recruiting
• Childhood cancers2 recruiting
• Endometrial cancer2 recruiting
• Multiple myeloma2 recruiting
• Myasthenia gravis2 recruiting
• Parkinson disease2 recruiting
• ALS (motor neurone disease)1 recruiting
• Asthma1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Endometriosis1 recruiting
• Glaucoma1 recruiting
• Glioblastoma1 recruiting
• Huntington's disease1 recruiting
• Lung cancer1 recruiting
• Macular degeneration1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple sclerosis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroblastoma1 recruiting
• Sarcoma1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Transcraneal Magnetic Stimulation for Treatment of Non-nociceptive Pain in Chronic Diseases

  NCT07888673· Source

• Completed

  Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy

  2024-517014-15-00· Phase 2/3· Source

• Terminated

  Functional and Affective Effects of a Brief tDCS Intervention in Fibromyalgia and Chronic Fatigue Syndrome

  NCT07573709· Source

• Completed

  CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2).

  NCT05797792· Phase 3· Source

• Completed

  CHemical OptImization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy 2 (CHOICE2TRIAL)

  2023-504262-32-01· Phase 3· Source

• Completed

  Development of a Molecular Diagnostic Tool for Endometrial Cancer.

  NCT06192017· Source

• Completed

  Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

  NCT05794139· Phase 2· Source

• Completed

  Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2-positive non-resectable locally advanced or metastatic breast cancer “TrasTUCAN Study”

  NCT05583110· Phase 1/2· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Source

• Completed

  Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED

  NCT05520723· Phase 2· Source

• Completed

  Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhibitor therapy

  2022-500652-37-00· Phase 2· Source

• Completed

  Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

  NCT05291091· Phase 2· Source

• Active, not recruiting

  Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

  NCT05257408· Phase 3· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Source

• Completed

  COVID-19, Patients' Evolution and the Influence of the Pandemic on Health Care and Outcomes in Chronic Diseases

  NCT05168722· Source

• Completed

  Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

  NCT05002569· Phase 3· Source

• Completed

  A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis

  NCT05021536· Phase 3· Source

• Completed

  SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS

  2024-519633-35-00· Phase 4· Source

• Active, not recruiting

  Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

  NCT04827953· Phase 1/2· Source

• Completed

  A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

  NCT04660344· Phase 3· Source

• Completed

  Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04833114· Phase 3· Source

• Recruiting

  A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

  NCT04710576· Phase 2· Source

• Completed

  A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

  NCT04567615· Phase 2· Source

• Completed

  Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1)

  NCT04797780· Phase 3· Source

• Completed

  A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

  NCT04309474· Phase 2· Source

• Completed

  A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

  NCT04374136· Phase 3· Source

• Completed

  A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health

  NCT04293523· Source

• Completed

  Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study

  NCT04134390· Phase 2· Source

• Completed

  Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease

  NCT03885713· Phase 4· Source

• Active, not recruiting

  A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

  NCT03981796· Phase 3· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Source

• Completed

  A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

  NCT03656536· Phase 3· Source

• Active, not recruiting

  A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

  NCT03778957· Phase 3· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Source

• Completed

  Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

  NCT03250338· Phase 3· Source

• Completed

  A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Resection or Ablation

  2023-508726-10-00· Phase 3· Source

• Completed

  Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

  NCT03555422· Phase 3· Source

• Completed

  Ixazomib Rollover Study

  NCT02924272· Phase 2· Source

• Active, not recruiting

  A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

  NCT02655016· Phase 3· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· Source

• Active, not recruiting

  AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

  NCT02511106· Phase 3· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Source

• Completed

  Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

  NCT01744249· Phase 2/3· Source

Trial sites

• Hospital Universitario Donostia105 trials
• Donostia University Hospital0 trials
• Hospital de Donostia3 trials
• Hospital Donostia1 trial
• Hospital Donostia /ID# 2180341 trial
• Hospital Donostia - Osidonostialdea0 trials
• Hospital Universitario de Donostia9 trials
• Hospital Universitario De Donostia /ID# 2631550 trials
• Hospital Universitario de Donostia, Servicio De Neurologia, Consultas Externas Neurologia, San Sebastian, Guipúzcoa1 trial
• Hospital Universitario de Donostia (Site 0671)1 trial
• Hospital Universitario de Donostia (Site 1602)0 trials
• Hospital Universitario Donostia20 trials
• Hospital Universitario Donostia (HUD)1 trial
• Hospital Universitario Donostia /ID# 2764040 trials
• Hosp. Univ. Donostia0 trials
• Hospital Universitario de Donostia1 trial
• Hospital Universitario de Donostia12 trials
• Hospital Universitario de Donostia1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Frontotemporal dementia17 works · 3 trials